Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

5 things you need to know about FDA and COVID-19 vaccines

By Brian Buntz | October 23, 2020

COVID-19 coronavirus

[Photo by Fusion Medical Animation on Unsplash]

There was no clear bombshell in the first meeting of an FDA advisory committee dedicated to COVID-19 vaccines. There were, however, several conclusions. 

Known as the Vaccines and Related Biological Products Advisory Committee (VRBAC), the meeting yesterday provided an overview of the steps medical and government authorities are taking to approve COVID-19 vaccines. 

Here are five key points from the meeting:

1. The government won’t mandate vaccines

The group also stressed that the federal government cannot mandate vaccines. “Mandates have been shown to increase coverage in some settings, but the federal government would not be mandating use of these vaccines,” said Dr. Amanda Cohn, chief medical officer at CDC’s National Center for Immunization and Respiratory Diseases. “Organizations, such as a hospital with licensed products, do have the capability of asking their workers to get the vaccine.” But in the context of an emergency use authorization, individuals will have “the right to refuse the vaccine,” Cohn said.   

The panel also discussed the need for a COVID-19 vaccine in settings such as nursing homes, prisons and medical facilities.

2. Data-based approach to COVID-19 vaccine approval comes with challenges

The panel stressed the need for scientific rigor in the development of vaccines for the novel coronavirus. The prospect of gathering data from populations such as individuals with comorbidities, the elderly in addition to pregnant and nursing women, however, is generally limited, panelists acknowledged. 

There’s a need to recruit “individuals who reflect the pandemic — in particular, individuals who are at risk of severe COVID,” said Dr. Hilary Marston, a medical officer with the National Institute of Allergy and Infectious Diseases.

There is also a dearth of COVID-19 vaccine trial data involving children. The Pfizer trial is unique in its enrollment of individuals as young as 12 years old. Most trials typically start at the age of 18.  

The panel recommended that trials continue if a vaccine is granted emergency use authorization. Pfizer, Johnson & Johnson and the trade group BIO have asked for clinical trial guidance from FDA in the event a vaccine becomes available. In particular, officials at the companies worry that attracting trial participants will become difficult if they realized they might receive a placebo. Prior guidance from FDA stated that the agency “does not consider availability of a COVID-19 vaccine under EUA, in and of itself, as grounds for stopping blinded follow-up in an ongoing clinical trial.”

If FDA grants emergency use of a vaccine before a clinical trial is completed, however, the prospect of determining how long the vaccine is effective could be difficult. 

3. Concerns about the lack of trial diversity

Moderna’s clinical trial for a COVID-19 vaccine hit a snag earlier this year for failing to recruit sufficient numbers of minority patients. The company is not alone. Several COVID-19 trials have struggled to recruit from diverse communities.

4. Risk of COVID-19 vaccine-induced enhanced disease is a concern

There is no proof that a vaccine for the novel coronavirus could exacerbate a COVID-19 infection rather than guard against it. But scientists have observed antibodies can occasionally worsen infections in a number of virus families. Researchers, for instance, have observed antibody-dependent disease enhancement with the dengue virus.

5. Panelists are mindful of a vaccine-wary public

The nation’s top infectious disease expert, Dr. Anthony Fauci, recently lamented that there is growing mistrust among the public in the government’s steps to combat the pandemic. “It’s the elephant in the room,” he said in a video posted by the watchdog group the Project on Government Oversight. 

The acting chair of the VRBAC Arnold Monto stressed the importance of transparency.

Several panelists in the VRBAC meeting stressed the need to build public trust in vaccines.

“We need to ensure the trust of the covid-19 vaccine and vaccines in general,” said Dr Doran Fink, a deputy director at FDA’s Center for Biologics Evaluation and Research division. “Widespread deployment of a weakly effective COVID-19 vaccine could result in more harm than good,” he added. 


Filed Under: Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, FDA, vaccine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE